Effect of Continuous Positive Airway Pressure on Lipid Profiles in Obstructive Sleep Apnea: A Meta-Analysis

dc.contributor.authorChen, Baixin
dc.contributor.authorGuo, Miaolan
dc.contributor.authorPeker, Yüksel
dc.contributor.authorSalord, Neus
dc.contributor.authorDrager, Luciano F.
dc.contributor.authorLorenzi-Filho, Geraldo
dc.contributor.authorTang, Xiangdong
dc.contributor.authorLi, Yun
dc.date.accessioned2022-03-04T11:38:27Z
dc.date.available2022-03-04T11:38:27Z
dc.date.issued2022-01-25
dc.date.updated2022-03-03T11:51:04Z
dc.description.abstractBackground: Obstructive sleep apnea (OSA) is associated with dyslipidemia. However, the effects of continuous positive airway pressure (CPAP) treatment on lipid profiles are unclear. Methods: PubMed/Medline, Embase and Cochrane were searched up to July 2021. Randomized controlled trials (RCTs) of CPAP versus controls with >= 4 weeks treatment and reported pre- and post-intervention lipid profiles were included. Weighted mean difference (WMD) was used to assess the effect size. Meta-regression was used to explore the potential moderators of post-CPAP treatment changes in lipid profiles. Results: A total of 14 RCTs with 1792 subjects were included. CPAP treatment was associated with a significant decrease in total cholesterol compared to controls (WMD = -0.098 mmol/L, 95% CI = -0.169 to -0.027, p = 0.007, I-2 = 0.0%). No significant changes in triglyceride, high-density lipoprotein nor low-density lipoprotein were observed after CPAP treatment (all p > 0.2). Furthermore, meta-regression models showed that age, gender, body mass index, daytime sleepiness, OSA severity, follow-up study duration, CPAP compliance nor patients with cardiometabolic disease did not moderate the effects of CPAP treatment on lipid profiles (all p > 0.05). Conclusions: CPAP treatment decreases total cholesterol at a small magnitude but has no effect on other markers of dyslipidemia in OSA patients. Future studies of CPAP therapy should target combined treatment strategies with lifestyle modifications and/or anti-hyperlipidemic medications in the primary as well as secondary cardiovascular prevention models.
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn2077-0383
dc.identifier.pmid35160050
dc.identifier.urihttps://hdl.handle.net/2445/183777
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm11030596
dc.relation.ispartofJournal of Clinical Medicine, 2022, vol 11, num 3
dc.relation.urihttps://doi.org/10.3390/jcm11030596
dc.rightscc by (c) Chen, Baixin et al, 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationSíndromes d'apnea del son
dc.subject.classificationTrastorns del metabolisme dels lípids
dc.subject.otherSleep apnea syndromes
dc.subject.otherLipid metabolism disorders
dc.titleEffect of Continuous Positive Airway Pressure on Lipid Profiles in Obstructive Sleep Apnea: A Meta-Analysis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
jcm-11-00596-v2.pdf
Mida:
743.08 KB
Format:
Adobe Portable Document Format